Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CASSAVA SCIENCES, INC.

(SAVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

--Street Color: SEC Investigating Whether Cassava Sciences Manipulated Results of Alzheimer's Study

11/17/2021 | 09:25am EST


ę MT Newswires 2021
All news about CASSAVA SCIENCES, INC.
01/24Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
AQ
01/24B. Riley Lowers Cassava Sciences' Price Target to $72 from $108 After Revising Cost Cap..
MT
01/20Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
AQ
01/12SOCIAL BUZZ : Wallstreetbets Stocks Mixed Premarket Wednesday
MT
01/06CASSAVA SCIENCES INC : Change in Directors or Principal Officers, Financial Statements and..
AQ
01/06SOCIAL BUZZ : Wallstreetbets Stocks Gets Spooked by Hawkish Fed; Shares Mostly Lower Pre-B..
MT
2021Cassava Sciences Launches Website to Back Phase 3 Studies of Simufilam for Alzheimer's ..
MT
2021Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam..
MT
2021Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam..
GL
2021Cassava Sciences, Inc. - Science Journal Finds No Evidence to Support Claims of Data Ma..
AQ
More news
Analyst Recommendations on CASSAVA SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -32,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -48,6x
Yield 2021 -
Capitalization 1 601 M 1 601 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 24,0x
Nbr of Employees 11
Free-Float -
Chart CASSAVA SCIENCES, INC.
Duration : Period :
Cassava Sciences, Inc. Technical Analysis Chart | SAVA | US14817C1071 | MarketScreener
Technical analysis trends CASSAVA SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 40,02 $
Average target price 128,67 $
Spread / Average Target 222%
EPS Revisions
Managers and Directors
Remi Barbier Chairman, President & Chief Executive Officer
Eric J. Schoen Chief Financial Officer
Nadav Friedmann Director, Chief Operating & Medical Officer
James W. Kupiec Chief Clinical Development Officer
Michael Zamloot Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
CASSAVA SCIENCES, INC.-8.42%1 601
GILEAD SCIENCES, INC.-5.19%86 352
REGENERON PHARMACEUTICALS-4.49%63 067
VERTEX PHARMACEUTICALS3.42%57 743
WUXI APPTEC CO., LTD.-7.49%50 700
BIONTECH SE-39.30%37 796